Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.

ABSTRACT:

Background

Human epidermal growth factor receptor 2 (HER2)-mutant lung cancer remains an orphan of specific targeted therapy. The variable responses to anti-HER2 therapies in these patients prompt us to examine impact of HER2 variants and co-mutations on responses to anti-HER2 treatments in lung cancer.

Patients and methods

Patients with stage IV/recurrent HER2-mutant lung cancers identified through next-generation sequencings were recruited from seven hospitals. The study comprised a cohort A to establish the patterns of HER2 variants and co-mutations in lung cancer and a cohort B to assess associations between HER2 variants, co-mutations, and clinical outcomes.

Results

The study included 118 patients (cohort A, n = 86; cohort B, n = 32). Thirty-one HER2 variants and

SUBMITTER: Fang W 

PROVIDER: S-EPMC7066719 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature